Cue Biopharma
CUE
36 hedge funds and large institutions have $15.2M invested in Cue Biopharma in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 3 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0.06% less ownership
Funds ownership: 0.59% → 0.53% (-0.06%)
3% less funds holding
Funds holding: 37 → 36 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
53% less capital invested
Capital invested by funds: $32.4M → $15.2M (-$17.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$181K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$151K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$118K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$112K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.22M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$724K |
| 3 |
Morgan Stanley
New York
|
-$190K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$103K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$101K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $21K | +$2.72K | +15 | +11% |
|
|
DOA
27
D'Orazio & Associates
Falls Church,
Virginia
| $19K | -$24.3K | -134 | -50% |
|
|
28
New York State Common Retirement Fund
Albany,
New York
| $15K | -$101K | -554 | -84% |
|
29
Legal & General Group
London,
United Kingdom
| $12K | – | – | – |
|
|
SO
30
STRS Ohio
Columbus,
Ohio
| $11K | – | – | – |
|
|
AIP
31
Ameritas Investment Partners
Lincoln,
Nebraska
| $7K | – | – | – |
|
|
MAM
32
Meeder Asset Management
Dublin,
Ohio
| $4K | -$5.63K | -31 | -51% |
|
33
Bank of Montreal
Toronto,
Ontario, Canada
| $4K | +$4.54K | +25 | +625% |
|
34
BNP Paribas Financial Markets
Paris,
France
| $1.42K | -$1.63K | -9 | -47% |
|
|
LTFS
35
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
PAWC
36
P.A.W. Capital
Greenwich,
Connecticut
| – | -$724K | -2,667 | Closed |
|
37
Barclays
London,
United Kingdom
| – | -$60K | -221 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$26K | -94 | Closed |
|
CUE Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2018, worth a combined $15.2M — down 53% from $32.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CUE and 2 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 14 added.
The largest buyer was Sphera Funds Management, adding an estimated $181K. The largest seller was Vanguard Group, cutting an estimated $2.22M.
- 36 institutional investors held Cue Biopharma (CUE) as of Q4 2018, down from 37 in Q3 2018.
- Funds reported $15.2M of Cue Biopharma stock for Q4 2018, down 53% quarter-over-quarter.
- 2 funds opened new Cue Biopharma positions in Q4 2018 and 3 closed out, a net change of -1 holder.
- The largest Cue Biopharma buyer in Q4 2018 was Sphera Funds Management, an estimated $181K added.
- The largest Cue Biopharma seller in Q4 2018 was Vanguard Group, an estimated $2.22M sold.
Based on aggregated 13F filings for Q4 2018.